Cash flow Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-05 pm EST			5-day change	1st Jan Change
169.70 ^USD	+1.67%		-3.87%	+37.80%

11:51am	Jazz Pharmaceuticals plc to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex®? (Cannabidiol) Outcomes in Treatment-Resistant Epilepsies At the American Epilepsy Society 2025 Annual Meeting	CI
Dec. 02	Jazz Pharmaceuticals plc to Present Pivotal Phase 3 Results of Ziihera®? (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCOGastrointestinal Cancers Symposium	CI

6872d820ccf7f49fd2b21394fbc063.fT5L0OeKAsP0zBJ9yfiKmxrdDa5e4lMj1dBNCOgu4tA.PGkhvYbQUPSnu3Q1hMz63UCQXOUV0xkSl7kMUJhZmqkfYXmept8vopGGIg

Published financial data: JAZZ PHARMACEUTICALS PLC

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	2.36B	3.09B	3.66B	3.83B	4.07B
Total Revenues	2.36B	3.09B	3.66B	3.83B	4.07B
Cost of Goods Sold, Total	149M	218M	267M	284M	311M
Gross Profit	2.21B	2.88B	3.39B	3.55B	3.76B
Selling General & Admin Expenses, Total	880M	1.25B	1.42B	1.31B	1.42B
R&D Expenses	310M	476M	555M	824M	854M
Amortization of Goodwill and Intangible Assets - (IS)	260M	526M	599M	608M	627M
Other Operating Expenses, Total	1.45B	2.25B	2.57B	2.74B	2.9B
Operating Income	765M	622M	818M	811M	862M
Interest Expense, Total	-94.62M	-279M	-300M	-355M	-344M
Interest And Investment Income	-	-	11.5M	65.1M	106M
Net Interest Expenses	-94.62M	-279M	-288M	-289M	-238M
Income (Loss) On Equity Invest.	-2.96M	-714K	-9.92M	-3.01M	-1.66M
Currency Exchange Gains (Loss)	-3.27M	-4.35M	-19.01M	8.79M	-8.18M
EBT, Excl. Unusual Items	665M	339M	501M	527M	614M
Restructuring Charges	-	-	-32.38M	-	-
Merger & Related Restructuring Charges	-	-452M	-273M	-151M	-135M
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-136M	-	-134M	-61.7M	-
In Process R&D Expenses	-251M	-	-444M	-19M	-10M
Legal Settlements	-	-	-	-	-
Other Unusual Items	-5.09M	-	-	-	-
EBT, Incl. Unusual Items	272M	-114M	-383M	295M	469M
Income Tax Expense	33.52M	216M	-159M	-120M	-91.43M
Earnings From Continuing Operations	239M	-330M	-224M	415M	560M
Net Income to Company	239M	-330M	-224M	415M	560M
Minority Interest	-	-	-	-	-
Net Income - (IS)	239M	-330M	-224M	415M	560M
Net Income to Common Incl Extra Items	239M	-330M	-224M	415M	560M
Net Income to Common Excl. Extra Items	239M	-330M	-224M	415M	560M
Per Share Items
Net EPS - Basic	4.28	-5.52	-3.58	6.55	9.06
Basic EPS - Continuing Operations	4.28	-5.52	-3.58	6.55	9.06
Basic Weighted Average Shares Outstanding	55.71M	59.69M	62.54M	63.29M	61.84M
Net EPS - Diluted	4.22	-5.52	-3.58	6.1	8.65
Diluted EPS - Continuing Operations	4.22	-5.52	-3.58	6.1	8.65
Diluted Weighted Average Shares Outstanding	56.52M	59.69M	62.54M	72.07M	66.01M
Normalized Basic EPS	7.46	3.54	5.01	5.2	6.2
Normalized Diluted EPS	7.35	3.54	5.01	4.57	5.81
American Depositary Receipts Ratio (ADR)	0.07	0.07	0.07	0.07	0.07
Supplemental Items
EBITDA	1.04B	1.17B	1.45B	1.45B	1.52B
EBITA	1.03B	1.15B	1.42B	1.42B	1.49B
EBIT	765M	622M	818M	811M	862M
EBITDAR	1.07B	1.2B	1.47B	1.48B	1.55B
Total Revenues (As Reported)	2.36B	3.09B	3.66B	3.83B	4.07B
Effective Tax Rate - (Ratio)	12.32	-190.32	41.45	-40.66	-19.51
Current Domestic Taxes	19.44M	25.77M	61.55M	77.34M	97.68M
Current Foreign Taxes	151M	121M	72.06M	62.96M	19.22M
Total Current Taxes	170M	147M	134M	140M	117M
Deferred Domestic Taxes	-32.46M	-5.39M	-62.01M	-10.92M	-20.02M
Deferred Foreign Taxes	-104M	74.59M	-230M	-249M	-188M
Total Deferred Taxes	-137M	69.2M	-292M	-260M	-208M
Normalized Net Income	415M	212M	313M	329M	384M
Interest on Long-Term Debt	111M	90.2M	33.23M	33.18M	40.44M
Supplemental Operating Expense Items
Advertising Expense	99.6M	162M	109M	92.2M	107M
Selling and Marketing Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	846M	1.03B	1.63B	1.48B	1.52B
Net Rental Expense, Total	25.61M	29.42M	24.76M	25.74M	29.97M
Imputed Operating Lease Interest Expense	9.63M	15.57M	9.9M	12.57M	13.8M
Imputed Operating Lease Depreciation	15.98M	13.85M	14.86M	13.17M	16.17M
Stock-Based Comp., COGS (Total)	7.37M	9.96M	12.49M	15.05M	14.8M
Stock-Based Comp., R&D Exp. (Total)	29.24M	43.76M	57.52M	64.85M	74.67M
Stock-Based Comp., SG&A Exp. (Total)	84.38M	135M	152M	147M	159M
Total Stock-Based Compensation	121M	189M	222M	227M	248M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	1.06B	591M	881M	1.51B	2.41B
Short Term Investments	1.08B	-	-	120M	580M
Trading Asset Securities, Total	-	-	-	3.78M	959K
Total Cash And Short Term Investments	2.13B	591M	881M	1.63B	2.99B
Accounts Receivable, Total	396M	563M	651M	706M	717M
Total Receivables	396M	563M	651M	706M	717M
Inventory	95.4M	1.07B	714M	597M	480M
Prepaid Expenses	62.42M	131M	91.91M	185M	177M
Other Current Assets, Total	152M	252M	267M	317M	261M
Total Current Assets	2.84B	2.61B	2.61B	3.44B	4.63B
Gross Property Plant And Equipment	325M	429M	409M	368M	389M
Accumulated Depreciation	-67.59M	-85.37M	-108M	-133M	-162M
Net Property Plant And Equipment	257M	343M	301M	235M	227M
Long-term Investments	4.5M	5M	5.5M	4.7M	4.33M
Goodwill	958M	1.83B	1.69B	1.75B	1.72B
Other Intangibles, Total	2.2B	7.15B	5.79B	5.42B	4.76B
Deferred Tax Assets Long-Term	255M	311M	376M	478M	560M
Deferred Charges Long-Term	5.24M	12.03M	9.25M	6.48M	9.49M
Other Long-Term Assets, Total	21.22M	35.81M	49.64M	62.76M	110M
Total Assets	6.54B	12.3B	10.84B	11.39B	12.01B
Liabilities
Accounts Payable, Total	26.94M	100M	90.76M	103M	77.87M
Accrued Expenses, Total	315M	588M	758M	748M	822M
Current Portion of Long-Term Debt	249M	46.23M	31M	605M	31M
Current Portion of Leases	14.46M	15.76M	15.94M	19.45M	14.78M
Current Income Taxes Payable	25.2M	9.61M	7.72M	35.07M	18.76M
Unearned Revenue Current, Total	2.55M	2.09M	463K	-	-
Other Current Liabilities	20.28M	46.9M	29.46M	26.26M	74.19M
Total Current Liabilities	654M	809M	933M	1.54B	1.04B
Long-Term Debt	1.85B	6.02B	5.69B	5.11B	6.08B
Long-Term Leases	140M	93.47M	77.05M	64.26M	43.5M
Unearned Revenue Non Current	2.32M	463K	-	-	-
Deferred Tax Liability Non Current	130M	1.3B	944M	848M	677M
Other Non Current Liabilities	101M	111M	102M	96.3M	82.05M
Total Liabilities	2.88B	8.33B	7.75B	7.66B	7.92B
Common Stock, Total	6K	6K	6K	6K	6K
Additional Paid In Capital	2.63B	3.53B	3.48B	3.7B	3.91B
Retained Earnings	1.16B	830M	734M	879M	1.13B
Comprehensive Income and Other	-134M	-400M	-1.12B	-842M	-947M
Total Common Equity	3.66B	3.97B	3.09B	3.74B	4.09B
Total Equity	3.66B	3.97B	3.09B	3.74B	4.09B
Total Liabilities And Equity	6.54B	12.3B	10.84B	11.39B	12.01B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	56.33M	61.74M	63.33M	62.35M	60.73M
ECS Total Common Shares Outstanding	56.17M	61.63M	63.21M	62.26M	60.63M
Book Value / Share	65.15	64.34	48.82	60.03	67.52
Tangible Book Value	506M	-5.01B	-4.4B	-3.43B	-2.38B
Tangible Book Value Per Share	9.02	-81.36	-69.63	-55.16	-39.22
Total Debt	2.25B	6.17B	5.82B	5.8B	6.17B
Net Debt	119M	5.58B	4.94B	4.17B	3.17B
Debt Equivalent Oper. Leases	205M	235M	198M	206M	240M
Equity Method Investments, Total	-	-	-	-	-
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	16M	21.55M	20.79M	25.6M	20.16M
Inventories - Work In Process, Total	45.76M	887M	518M	432M	312M
Inventories - Finished Goods, Total	33.64M	164M	176M	140M	149M
Land - (BS)	47.56M	64.01M	68.94M	70.91M	71.9M
Machinery, Total	63.81M	99.72M	100M	108M	116M
Full Time Employees	1.94K	3.2K	2.8K	2.8K	2.8K
Accumulated Allowance for Doubtful Accounts (Supple)	50K	13.81M	17.84M	21.14M	32.69M

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	239M	-330M	-224M	415M	560M
Depreciation & Amortization - CF	18.67M	26.71M	30.3M	30.41M	32.75M
Amortization of Goodwill and Intangible Assets - (CF)	260M	526M	599M	608M	627M
Depreciation & Amortization, Total	278M	552M	629M	639M	660M
Amortization of Deferred Charges, Total - (CF)	56.66M	-	-	-	-
(Gain) Loss From Sale Of Asset	-	-	37.7M	-	-
Asset Writedown & Restructuring Costs	387M	-	578M	80.01M	10M
(Income) Loss On Equity Investments - (CF)	5.44M	-	-	-	-
Stock-Based Compensation (CF)	121M	189M	222M	227M	248M
Provision and Write-off of Bad Debts	15M	19.67M	14.54M	11.11M	27.76M
Other Operating Activities, Total	-117M	395M	4.63M	-75.05M	-33.36M
Change In Accounts Receivable	-38.65M	-92.74M	-90.14M	-51.88M	-21.12M
Change In Inventories	-30.54M	-48.86M	-49.64M	-13.42M	-45.54M
Change In Accounts Payable	-18.94M	57.02M	-11.22M	9.6M	-20.07M
Change in Unearned Revenues	-4.72M	-2.3M	-2.09M	-463K	-
Change In Income Taxes	13.04M	-15.52M	-1.69M	25.22M	-14.74M
Change in Other Net Operating Assets	-5.64M	54.45M	165M	-173M	24.75M
Cash from Operations	900M	779M	1.27B	1.09B	1.4B
Capital Expenditure	-15M	-27.64M	-29.05M	-23.96M	-38.07M
Sale of Property, Plant, and Equipment	14.26M	-	-	-	-
Cash Acquisitions	-	-6.23B	-	-	-
Divestitures	-	-	53M	-	-
Sale (Purchase) of Intangible assets	-364M	-17.89M	-469M	-19M	-10M
Investment in Marketable and Equity Securities, Total	-643M	1.07B	-1.04M	-120M	-460M
Cash from Investing	-1.01B	-5.21B	-446M	-163M	-508M
Short Term Debt Issued, Total	500M	-	-	-	-
Long-Term Debt Issued, Total	981M	5.19B	-	-	981M
Total Debt Issued	1.48B	5.19B	-	-	981M
Short Term Debt Repaid, Total	-500M	-	-	-	-
Long-Term Debt Repaid, Total	-390M	-1.32B	-582M	-31M	-606M
Total Debt Repaid	-890M	-1.32B	-582M	-31M	-606M
Issuance of Common Stock	99.68M	135M	98.02M	46.46M	20.65M
Repurchase of Common Stock	-163M	-35.6M	-45.5M	-321M	-369M
Other Financing Activities, Total	-	-	-	-	-5.72M
Cash from Financing	528M	3.97B	-529M	-305M	20.52M
Foreign Exchange Rate Adjustments	374K	-3.21M	-6.22M	1.14M	-1.68M
Net Change in Cash	420M	-466M	290M	625M	907M
Supplemental Items
Cash Interest Paid	42.47M	138M	271M	333M	315M
Cash Income Tax Paid (Refund)	227M	271M	94.68M	178M	115M
Levered Free Cash Flow	415M	-45.2M	1.11B	1.05B	1.43B
Unlevered Free Cash Flow	417M	129M	1.3B	1.27B	1.65B
Change In Net Working Capital	81.26M	956M	-434M	54.64M	-251M
Net Debt Issued / Repaid	592M	3.87B	-582M	-31M	375M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	7.92	4.13	4.42	4.56	4.6
Return on Total Capital	8.86	4.85	5.37	5.5	5.44
Return On Equity %	7.05	-8.65	-6.36	12.16	14.31
Return on Common Equity	7.05	-8.65	-6.36	12.16	14.31
Margin Analysis
Gross Profit Margin %	93.7	92.97	92.7	92.59	92.36
SG&A Margin	37.23	40.47	38.79	34.09	34.79
EBITDA Margin %	44.16	37.97	39.56	37.8	37.4
EBITA Margin %	43.37	37.11	38.73	37.01	36.59
EBIT Margin %	32.39	20.11	22.35	21.14	21.18
Income From Continuing Operations Margin %	10.1	-10.65	-6.12	10.82	13.77
Net Income Margin %	10.1	-10.65	-6.12	10.82	13.77
Net Avail. For Common Margin %	10.1	-10.65	-6.12	10.82	13.77
Normalized Net Income Margin	17.57	6.84	8.55	8.59	9.43
Levered Free Cash Flow Margin	17.54	-1.46	30.37	27.46	35.24
Unlevered Free Cash Flow Margin	17.65	4.17	35.49	33.24	40.53
Asset Turnover
Asset Turnover	0.39	0.33	0.32	0.34	0.35
Fixed Assets Turnover	8.95	10.31	11.35	14.3	17.62
Receivables Turnover (Average Receivables)	6.28	6.45	6.02	5.65	5.72
Inventory Turnover (Average Inventory)	1.71	0.37	0.3	0.43	0.58
Short Term Liquidity
Current Ratio	4.34	3.23	2.79	2.24	4.46
Quick Ratio	3.87	1.43	1.64	1.52	3.57
Operating Cash Flow to Current Liabilities	1.38	0.96	1.36	0.71	1.34
Days Sales Outstanding (Average Receivables)	58.26	56.61	60.59	64.6	63.98
Days Outstanding Inventory (Average Inventory)	213.83	979.36	1.22K	842.13	634.63
Average Days Payable Outstanding	80.26	19.43	-380.92	211.33	170.29
Cash Conversion Cycle (Average Days)	191.83	1.02K	1.66K	695.41	528.33
Long Term Solvency
Total Debt/Equity	61.54	155.72	188.52	155.21	150.64
Total Debt / Total Capital	38.1	60.89	65.34	60.82	60.1
LT Debt/Equity	54.34	154.15	187	138.5	149.52
Long-Term Debt / Total Capital	33.64	60.28	64.81	54.27	59.66
Total Liabilities / Total Assets	44.01	67.76	71.52	67.2	65.92
EBIT / Interest Expense	8.09	2.23	2.73	2.29	2.5
EBITDA / Interest Expense	11.3	4.32	4.91	4.16	4.51
(EBITDA - Capex) / Interest Expense	11.14	4.22	4.81	4.09	4.39
Total Debt / EBITDA	2.11	5.13	3.95	3.93	3.97
Net Debt / EBITDA	0.11	4.64	3.35	2.83	2.04
Total Debt / (EBITDA - Capex)	2.14	5.25	4.03	4	4.07
Net Debt / (EBITDA - Capex)	0.11	4.74	3.42	2.87	2.1
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	9.34	30.91	18.26	4.78	6.12
Gross Profit, 1 Yr. Growth %	8.89	29.89	17.93	4.65	5.86
EBITDA, 1 Yr. Growth %	3.08	12.56	23.21	-1.31	4.99
EBITA, 1 Yr. Growth %	2.8	12.01	23.44	-1.34	4.93
EBIT, 1 Yr. Growth %	19.17	-18.69	31.44	-3.39	6.28
Earnings From Cont. Operations, 1 Yr. Growth %	-54.41	-238.16	-32.03	-285.14	35.02
Net Income, 1 Yr. Growth %	-54.41	-238.16	-32.03	-285.14	35.02
Normalized Net Income, 1 Yr. Growth %	18.64	-48.67	47.95	0.98	16.44
Diluted EPS Before Extra, 1 Yr. Growth %	-53.58	-230.87	-35.13	-270.3	41.75
Accounts Receivable, 1 Yr. Growth %	11.38	42.09	15.64	8.33	1.55
Inventory, 1 Yr. Growth %	21.36	1.02K	-33.43	-16.39	-19.53
Net Property, Plant and Equip., 1 Yr. Growth %	-5.09	33.57	-12.24	-22.03	-3.4
Total Assets, 1 Yr. Growth %	18	88.17	-11.9	5.15	5.43
Tangible Book Value, 1 Yr. Growth %	-302.54	-1.09K	-12.23	-21.97	-30.75
Common Equity, 1 Yr. Growth %	17.64	8.35	-22.18	21.11	9.55
Cash From Operations, 1 Yr. Growth %	15.87	-13.47	63.39	-14.15	27.83
Capital Expenditures, 1 Yr. Growth %	-62.62	84.22	5.08	-17.5	58.88
Levered Free Cash Flow, 1 Yr. Growth %	-26.09	-112.74	-2.5K	-6.36	36.17
Unlevered Free Cash Flow, 1 Yr. Growth %	-25.48	-69.07	906.58	-2.84	29.39
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	11.8	19.64	24.43	11.32	5.45
Gross Profit, 2 Yr. CAGR %	11.88	18.93	23.76	11.09	5.26
EBITDA, 2 Yr. CAGR %	5.79	7.72	17.77	18.76	1.79
EBITA, 2 Yr. CAGR %	5.7	7.3	17.58	19.06	1.75
EBIT, 2 Yr. CAGR %	3.4	-1.57	3.38	30.61	1.33
Earnings From Cont. Operations, 2 Yr. CAGR %	-26.95	-20.63	-3.1	12.18	58.11
Net Income, 2 Yr. CAGR %	-26.95	-20.63	-3.1	12.18	58.11
Normalized Net Income, 2 Yr. CAGR %	2.73	-22.26	-12.85	65.93	8.43
Diluted EPS Before Extra, 2 Yr. CAGR %	-23.97	-22.05	-7.86	5.11	55.37
Accounts Receivable, 2 Yr. CAGR %	22.59	25.8	28.19	11.93	4.89
Inventory, 2 Yr. CAGR %	34.22	269.41	173.59	-25.4	-17.97
Net Property, Plant and Equip., 2 Yr. CAGR %	13.28	12.59	8.27	-17.28	-13.21
Total Assets, 2 Yr. CAGR %	12.07	49.01	28.76	-3.75	5.29
Tangible Book Value, 2 Yr. CAGR %	-25.05	347.86	194.82	-17.25	-26.49
Common Equity, 2 Yr. CAGR %	15.21	12.9	-8.18	-2.92	15.18
Cash From Operations, 2 Yr. CAGR %	6.12	0.14	18.91	18.44	4.76
Capital Expenditures, 2 Yr. CAGR %	-14.18	-17.01	39.14	-6.89	14.48
Levered Free Cash Flow, 2 Yr. CAGR %	-20.12	-70.36	78.74	175.97	12.92
Unlevered Free Cash Flow, 2 Yr. CAGR %	-20.14	-51.99	76.45	486.25	12.12
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	13.45	17.84	19.18	17.5	9.56
Gross Profit, 3 Yr. CAGR %	13.65	17.58	18.59	17.03	9.32
EBITDA, 3 Yr. CAGR %	10.24	8	12.65	11.57	13.98
EBITA, 3 Yr. CAGR %	10.2	7.76	12.43	11.45	14.15
EBIT, 3 Yr. CAGR %	7.64	-4.56	8.39	1.93	21.94
Earnings From Cont. Operations, 3 Yr. CAGR %	-21.21	-9.66	-24.63	20.24	19.33
Net Income, 3 Yr. CAGR %	-21.21	-9.66	-24.63	20.24	19.33
Normalized Net Income, 3 Yr. CAGR %	8.17	-18.69	-3.66	-7.2	47.45
Diluted EPS Before Extra, 3 Yr. CAGR %	-19.07	-8.88	-26.68	13.08	16.13
Accounts Receivable, 3 Yr. CAGR %	20.94	28.77	22.32	21.19	8.36
Inventory, 3 Yr. CAGR %	30.18	172.6	108.65	84.29	-23.49
Net Property, Plant and Equip., 3 Yr. CAGR %	14.77	19.68	3.62	-2.95	-12.89
Total Assets, 3 Yr. CAGR %	8.45	33.21	25.07	20.35	-0.78
Tangible Book Value, 3 Yr. CAGR %	-25.27	77.18	160.14	89.28	-22.02
Common Equity, 3 Yr. CAGR %	10.49	12.87	-0.27	0.7	1.07
Cash From Operations, 3 Yr. CAGR %	9.08	-0.86	17.89	6.67	21.49
Capital Expenditures, 3 Yr. CAGR %	-19.67	10.71	-10.22	16.89	11.26
Levered Free Cash Flow, 3 Yr. CAGR %	-6.65	-58.87	29.26	44.66	118.07
Unlevered Free Cash Flow, 3 Yr. CAGR %	-7.57	-41.79	32.38	45.11	254.29
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	12.28	15.77	17.72	15.19	13.48
Gross Profit, 5 Yr. CAGR %	12.62	15.78	17.59	14.94	13.07
EBITDA, 5 Yr. CAGR %	9.4	9.28	13.19	9.22	8.49
EBITA, 5 Yr. CAGR %	9.33	9.12	13.1	9.11	8.35
EBIT, 5 Yr. CAGR %	6.53	-0.56	5.91	2.52	6.05
Earnings From Cont. Operations, 5 Yr. CAGR %	-6.25	-3.64	-14.41	-1.49	1.37
Net Income, 5 Yr. CAGR %	-6.25	-3.64	-14.41	-1.49	1.37
Normalized Net Income, 5 Yr. CAGR %	5.75	-10.24	-0.94	-3.5	1.84
Diluted EPS Before Extra, 5 Yr. CAGR %	-4.2	-2.94	-14.76	-3.52	-0.99
Accounts Receivable, 5 Yr. CAGR %	13.59	19.19	23.79	21.75	15.02
Inventory, 5 Yr. CAGR %	37.44	99.38	75.21	62.34	43.63
Net Property, Plant and Equip., 5 Yr. CAGR %	24.61	26.15	12.12	3.24	-3.47
Total Assets, 5 Yr. CAGR %	14.42	20.7	16.16	16.97	16.75
Tangible Book Value, 5 Yr. CAGR %	15.71	19.84	29.39	30.67	56.91
Common Equity, 5 Yr. CAGR %	18.02	16.13	2.61	6.27	5.64
Cash From Operations, 5 Yr. CAGR %	11.08	5.62	12.91	6.45	12.45
Capital Expenditures, 5 Yr. CAGR %	-16.04	23.33	0.07	3.3	-1.05
Levered Free Cash Flow, 5 Yr. CAGR %	-5.29	-35.07	16.87	10.13	22.75
Unlevered Free Cash Flow, 5 Yr. CAGR %	-5.62	-20.58	19.71	14.27	24.12